NI202000023A - Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. - Google Patents

Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.

Info

Publication number
NI202000023A
NI202000023A NI202000023A NI202000023A NI202000023A NI 202000023 A NI202000023 A NI 202000023A NI 202000023 A NI202000023 A NI 202000023A NI 202000023 A NI202000023 A NI 202000023A NI 202000023 A NI202000023 A NI 202000023A
Authority
NI
Nicaragua
Prior art keywords
compounds
monobactamic
chroman
treatment
bacterial infections
Prior art date
Application number
NI202000023A
Other languages
English (en)
Inventor
Biftu Tesfaye
Huang Xianhai
Liu Weiguo
Pan Weidong
Park Min
Pasternak Alexander
Sun Wanying
Tang Haifeng
zang Yi
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NI202000023A publication Critical patent/NI202000023A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a compuestos monobactámicos de la Fórmula I: o una sal de estos farmacéuticamente aceptable. La presente invención también se refiere a composiciones que comprenden un compuesto monobactámico de la invención o una sal de este farmacéuticamente aceptable y un portador farmacéuticamente aceptable. La invención además se refiere a métodos para tratar una infección bacteriana que comprende administrar al paciente una cantidad terapéuticamente eficaz de un compuesto de la invención, ya sea solo o en combinación con una cantidad terapéuticamente eficaz de un segundo antibiótico betalactámicos.
NI202000023A 2017-10-02 2020-03-24 Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. NI202000023A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762566779P 2017-10-02 2017-10-02

Publications (1)

Publication Number Publication Date
NI202000023A true NI202000023A (es) 2020-09-24

Family

ID=65994576

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202000023A NI202000023A (es) 2017-10-02 2020-03-24 Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.

Country Status (25)

Country Link
US (1) US11433055B2 (es)
EP (1) EP3691639B1 (es)
JP (1) JP7252948B2 (es)
KR (1) KR102425959B1 (es)
CN (1) CN111201021A (es)
AU (1) AU2018345523B2 (es)
BR (1) BR112020006381A8 (es)
CA (1) CA3076022C (es)
CL (1) CL2020000860A1 (es)
CO (1) CO2020004087A2 (es)
CR (1) CR20200148A (es)
DO (1) DOP2020000058A (es)
EA (1) EA202090604A1 (es)
GE (1) GEP20227406B (es)
IL (1) IL273306B (es)
JO (1) JOP20200130A1 (es)
MA (1) MA50629A (es)
MX (1) MX2020003581A (es)
NI (1) NI202000023A (es)
PE (1) PE20201256A1 (es)
PH (1) PH12020550107A1 (es)
SG (1) SG11202002575UA (es)
UA (1) UA126000C2 (es)
WO (1) WO2019070492A1 (es)
ZA (1) ZA202001721B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156697B (zh) * 2019-05-30 2022-05-06 常州沃腾化工科技有限公司 一种1,2-二甲基-1,4,5,6-四氢嘧啶的合成方法
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
MX2023000056A (es) 2020-07-02 2023-04-12 Incyte Corp Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022120048A1 (en) * 2020-12-03 2022-06-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Hdac inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺
US11932637B2 (en) * 2021-11-18 2024-03-19 Merck Sharp & Dohme Llc Chromane amidine monobactam compounds for the treatment of bacterial infections
WO2024019916A2 (en) * 2022-07-18 2024-01-25 Merck Sharp & Dohme Llc Chromane amidine monobactam compounds for the treatment of bacterial infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684722A (en) 1986-01-06 1987-08-04 E. R. Squibb & Sons, Inc. Monosulfactams
US5250691A (en) * 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
PT2308874E (pt) * 2005-12-07 2013-04-26 Basilea Pharmaceutica Ag Monobactamas ligadas por pontes, úteis como inibidores de beta-lactamase
EP1938822A1 (en) 2006-12-21 2008-07-02 Novartis AG Combination therapy for the treatment of airways disease
SI2627672T1 (sl) 2010-10-11 2018-10-30 Biogen International Neuroscience Gmbh Človeška protitelesa anti-tau
ES2542431T3 (es) 2010-11-29 2015-08-05 Pfizer Inc Monobactamas
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
US20150183854A1 (en) 2012-05-31 2015-07-02 Teijin Pharma Limited Therapeutic agent or prophylactic agent for dementia
US20140275007A1 (en) 2013-03-14 2014-09-18 Rempex Pharmaceuticals, Inc. Oxamazin antibiotics
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
AU2015236369B2 (en) 2014-03-24 2017-02-16 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
SG11201703391VA (en) * 2014-10-31 2017-05-30 Abbvie S À R L Substituted chromanes and method of use
FR3031423B1 (fr) * 2015-01-06 2018-11-30 Centre National De La Recherche Scientifique Procede et dispositif de conversion de courant et vehicule comportant un tel dispositif
WO2017106064A1 (en) * 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
BR112018067930B1 (pt) 2016-03-07 2024-02-15 Merck Sharp & Dohme Llc Composto, sal de ácido trifluoroacético, composição farmacêutica, e, uso de um composto

Also Published As

Publication number Publication date
EP3691639B1 (en) 2023-11-15
BR112020006381A2 (pt) 2020-09-24
GEP20227406B (en) 2022-08-25
IL273306B (en) 2022-04-01
CN111201021A (zh) 2020-05-26
KR102425959B1 (ko) 2022-07-27
PH12020550107A1 (en) 2020-12-07
PE20201256A1 (es) 2020-11-16
SG11202002575UA (en) 2020-04-29
JOP20200130A1 (ar) 2020-05-28
CO2020004087A2 (es) 2020-04-24
CA3076022C (en) 2023-01-17
BR112020006381A8 (pt) 2023-04-11
CL2020000860A1 (es) 2020-08-14
CR20200148A (es) 2020-05-22
US11433055B2 (en) 2022-09-06
EP3691639A1 (en) 2020-08-12
US20200297702A1 (en) 2020-09-24
AU2018345523B2 (en) 2021-10-21
AU2018345523A1 (en) 2020-03-26
WO2019070492A1 (en) 2019-04-11
UA126000C2 (uk) 2022-07-27
ZA202001721B (en) 2023-02-22
MX2020003581A (es) 2020-07-22
KR20200058520A (ko) 2020-05-27
IL273306A (en) 2020-04-30
CA3076022A1 (en) 2019-04-11
JP7252948B2 (ja) 2023-04-05
EA202090604A1 (ru) 2020-10-15
EP3691639A4 (en) 2021-03-31
JP2020536082A (ja) 2020-12-10
MA50629A (fr) 2021-03-31
DOP2020000058A (es) 2020-09-15

Similar Documents

Publication Publication Date Title
NI202000023A (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.
MX2018005382A (es) Compuestos de biaril-monobactam y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
PH12017502418A1 (en) 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors
BR112018067930A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
BR112013032770A2 (pt) composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
NZ596628A (en) Ketolide compounds having antimicrobial activity
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
MX2015012472A (es) Derivados de manosa para el tratamiento de infecciones bacterianas.
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
PE20200333A1 (es) Compuestos y metodos para tratar infecciones bacterianas
EA202090750A1 (ru) Производные глюконовой кислоты для применения в лечении и/или предупреждении инфекций, вызываемых микроорганизмами
AR127695A1 (es) Compuestos monobactámicos de cromano amidina para tratar las infecciones bacterianas
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv
CO2024002712A2 (es) Azálidos inmunomoduladores
TH1701007800A (th) ตัวยับยั้งเมทัลโล-บีตา-แลคทาเมส
UA110098C2 (uk) Композиція, що містить цефтаролін фозамілу, для лікування бактеріальної інфекції
CL2009000386A1 (es) Compuestos derivados de oxazolidinona; composición farmacéutica que contiene dichos compuestos; y su uso para prevenir o tratar una infección bacteriana.